Cancer

Profs. Canan Dagdeviren and Hugh Herr speak with CNN discuss their work aimed at empowering patients and doctors. Inspired by her aunt’s experience with breast cancer, Dagdeviren and her students are developing new wearable devices that could help detect cancer at an earlier stage. Says Herr of his work developing prosthetics that can be controlled by the human nervous system: “There will be a point where technology is so sophisticated that we can actually rebuild limbs after amputation that will be as good and, ultimately, they will be better than intact biological limbs.” Herr adds that in the future he hopes “the conversation will not be about human limitation anymore. It will be about human ability and human expression.”

Prof. Regina Barzilay has received the WebMD Health Heros award for her work developing a new system that uses AI to detect breast cancer up to 5 years earlier, reports WHDH. “We do have a right to know our risk and then we, together with our healthcare providers, need to manage them,” says Barzilay. 

CNN visits the lab of Prof. Canan Dagdeviren to learn more about her work developing wearable ultrasound devices that could help screen for early-stage breast cancer, monitor kidney health, and detect other cancers deep within the body. “Wearable technology will grow rapidly in the near future,” says Dagdeviren. “But in the far future, they will be one of the most powerful tools that we will be seeing in our daily life.” 

Prof. Ömer Yilmaz and his colleagues have discovered the potential health benefits and consequences of fasting, reports Max Kozlov for Nature. “There is so much emphasis on fasting and how long to be fasting that we’ve kind of overlooked this whole other side of the equation: what is going on in the refed state,” says Yilmaz.

MIT researchers have discovered how fasting impacts the regenerative abilities of intestinal stem cells, reports Ed Cara for Gizmodo. “The major finding of our current study is that refeeding after fasting is a distinct state from fasting itself,” explain Prof. Ömer Yilmaz and postdocs Shinya Imada and Saleh Khawaled. “Post-fasting refeeding augments the ability of intestinal stem cells to, for example, repair the intestine after injury.” 

Researchers from MIT and elsewhere are investigating the “pathways, risk factors, and molecules” involved in the development of colorectal cancer, reports Rick Sobey for The Boston Herald. “The research team has uncovered contributing causes to this rise in early-onset cases, including: overweight/obesity, physical inactivity, poor diet, and alterations in the gut microbiome,” writes Sobey.

MIT scientists have found that a potential treatment for Alzheimer’s disease involving flickering lights and low-pitched sound could also help prevent cognitive problems after cancer treatment, reports Clare Wilson for New Scientist. The treatment is aimed at stimulating 40 Hz brainwaves, which are linked to memory processing. The results suggest targeting such “brainwaves may result in broader benefits for the brain, including increasing the activity of immune cells and, most recently, boosting its drainage system, which could help clear a toxic protein called beta-amyloid.”
 

Bingxu Liu PhD '23 speaks with Science reporter Christie Wilcox about his work  studying STING, an immune protein that plays a key role in defending the human body against viruses, bacteria, and tumors. “STING is actually one of the most promising cancer immunotherapy targets,” explains Wilcox. “If you activate the STING pathway, it triggers a very strong immune response. But when it’s too strong, it can actually kill your T cells. Initial evidence suggest that T cells die because of some ion impact. Which begs the question: Can we just use STING to activate some parts of the immune response, like interferon, but also block the ion flow [that’s harming T cells]?” 

MIT researchers have developed new technology that allows vaccines to be directly inserted into the lymph nodes to target two of the most common mutations in the KRAS gene, which cause roughly one third of all cancers, reports Jaimie Seaton for Scientific American. “The team modified the small vaccine components to include a fatty acid, which enables the vaccine to effectively hitch a ride on albumin, a common protein found throughout the body,” explains Seaton. “Albumin serves as a molecular shuttle bus, with pockets on its surface where fatty acids can bind to it.”

Researchers from MIT and elsewhere have developed an AI model that is capable of identifying 3 ½ times more people who are at high-risk for developing pancreatic cancer than current standards, reports Felice J. Freyer for The Boston Globe. “This work has the potential to enlarge the group of pancreatic cancer patients who can benefit from screening from 10 percent to 35 percent,” explains Freyer. “The group hopes its model will eventually help detect risk of other hard-to-find cancers, like ovarian.”

Prof. Ron Weiss co-founded Strand Therapeutics, a biotech company developing mRNA therapies, reports Emily Mullin for Wired. “The notion is that genetic circuits can really have significant impact on safety and efficacy,” says Weiss. “This begins to really open up the door for creating therapies whose sophistication can match the underlying complexity of biology.”

Carmen Martin-Alonso PhD '23 speaks with Zakiya Whatley on the Science podcast to discuss her recent research focused on developing new methods to improve liquid biopsies for cancer. “I think this is super, super promising for the field of oncology where having more sensitive ctDNA-based liquid biopsies could really transform patient management,” says Alonso. “And in the same way as radio label converse agents have transformed imaging, we think that priming agents could transform the utility of liquid biopsies.”

Prof. Canan Dagdeviren and her team have developed a wearable ultrasound patch that can be used to screen for breast cancer at home, reports Grace Browne for Wired. “Dagdeviren wants to give people the opportunity to know what’s happening inside their bodies every day, the same way we check the weather forecast,” writes Browne.

A new analysis from MIT researchers has found that preventative screenings such as a colonoscopy and sigmoidoscopy can reduce cancer rates more than previous analyses suggested, reports Ernie Mundell for HealthDay. “Prior colon cancer screening studies found that regular colonoscopy/sigmoidoscopy reduced that rate by 25% -- to 0.75%,” explains Mundell. “But the new analysis took into account the number of participants in a colon cancer screening trial who decided, for whatever reason, to skip screening. When these "non-adherent" folks were eliminated from statistical calculations, the actual percentage of people who went on to develop colon cancer over a 10-year span fell to just 0.5%.”